RT Journal Article
SR Electronic
T1 COVID-19: age, Interleukin-6, C-Reactive Protein and lymphocytes as key clues from a multicentre retrospective study in Spain
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.13.20101345
DO 10.1101/2020.05.13.20101345
A1 Aurora Jurado
A1 María C. Martín
A1 Cristina Abad-Molina
A1 Antonio Orduña
A1 Alba Martínez
A1 Esther Ocaña
A1 Oscar Yarce
A1 Ana M. Navas
A1 Antonio Trujillo
A1 Luis Fernández
A1 Esther Vergara
A1 Beatriz Rodríguez
A1 Bibiana Quirant
A1 Eva Martínez-Cáceres
A1 Manuel Hernández
A1 Janire Perurena-Prieto
A1 Juana Gil
A1 Sergi Cantenys
A1 Gema González-Martínez
A1 María T. Martínez-Saavedra
A1 Ricardo Rojo
A1 Francisco M. Marco
A1 Sergio Mora
A1 Jesús Ontañón
A1 Marcos López-Hoyos
A1 Gonzalo Ocejo-Vinyals
A1 Josefa Melero
A1 Marta Aguilar
A1 Delia Almeida
A1 Silvia Medina
A1 María C. Vegas
A1 Yesenia Jiménez
A1 Álvaro Prada
A1 David Monzón
A1 Francisco Boix
A1 Vanesa Cunill
A1 Juan Molina
YR 2020
UL http://medrxiv.org/content/early/2020/06/06/2020.05.13.20101345.abstract
AB Background SARS-CoV-2 infection has widely spread to the hugest public health challenge to date, COVID-19 pandemic. Different fatality rates among countries are probably due to non-standardized records being carried out by local health authorities. Spanish case-fatality rate is 11.94%, far higher to those reported in Asia or by other European countries. A multicenter retrospective study was performed of demographic, clinical, laboratory and immunological features of 574 Spanish COVID-19 hospitalized patients and their outcomes. The use of use of renin-angiotensin system blockers was also analyzed as a risk factor.Results In this study, 27.7% of cases presented a mild curse, 42% a moderate one and for 30.3% of cases, the course was severe. Ages ranged from 18 to 98 (average 63.2). Fifty eight percent (58.9%) of patients were male. Interleukin 6 was higher as severity increased. On the other hand, CD8 lymphocyte count was significantly lower as severity grew and subpopulations CD4, CD8, CD19 and NK showed concordant lowering trends. Severity-related natural killer percent descents were evidenced just within aged cases. A significant severity-related decrease of CD4 lymphocytes was found in males. The use of renin-angiotensin system blockers was associated with moderate or mild disease courses.Conclusions Age and age-related comorbidities, such as dyslipidaemia, hypertension or diabetes, determined more frequent severe forms of the disease in this study than in previous literature cohorts. Our cases are older than those so far reported and clinical course of the disease is found to be impaired by age. Immunosenescence might be therefore a suitable explanation for immune system effectors severity-related hampering. Adaptive immunity would go exhausted and a huge ineffective and almost deleterious innate response would account for COVID-19 severity. Renin-angiotensin system blockers treatment in hypertensive patients has a protective effect as regarding COVID-19 severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Valladolid Este Research Ethics Commitee (Comite etico de Investigacion de Valladolid Este) Valladolid, SpainAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData referred are available as an anonymized data base under requirements approbed by our ethics committee